# Rocket Pharmaceuticals, Inc. (RCKT)

> Source: Nexqual · https://nexqual.com/RCKT · data as of 2026-10-23 15:00 UTC · cite as "Nexqual, Rocket Pharmaceuticals, Inc. (RCKT), nexqual.com/RCKT" · informational, not investment advice.

**Price:** USD 2.23 (-3.46% today) · US market open, as of October 23, 2026 at 15:00 UTC; quotes may be delayed. Prev close 2.31 · day 2.17–2.27 · 52w 2.17–5.45 · market cap $245M · NGM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $0K, net income -$17.3M, free cash flow -$170M (SEC filings).
- 1 of 80 tracked superinvestors hold RCKT (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 15 Form 4 filings, $708K; 15 not under a Rule 10b5-1 plan ($708K); 0 by opportunistic insiders, 7 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.57 on a 1–5 scale) (14 analysts), mean target USD 8.58 (range 2.95–15).
- Total return with dividends: 1Y -40.4% vs S&P 500 +14.8%; 5Y -92.5% vs S&P 500 +77.5%.
- Next earnings: 2026-11-05, EPS estimate USD -0.41, revenue estimate $182K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0K | $0K | $0K | $0K | $0K | $0K |
| Operating income | -$167M | -$224M | -$260M | -$273M | -$232M | -$192M |
| Net income | -$169M | -$222M | -$246M | -$259M | -$223M | -$17.3M |
| EPS (diluted) | -$2.67 | -$3.26 | -$2.92 | -$2.73 | -$2.01 | — |
| Free cash flow | -$129M | -$187M | -$211M | -$216M | -$190M | -$170M |
| Cash + short-term investments | $389M | $356M | $408M | $372M | $189M | — |
| Total debt | $0K | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 0.7x · FCF yield -69.61% · Earnings yield -7.05%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold RCKT. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | 0.12% | $13.4M | Added +10.0% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 15 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Wilson Martin | General Counsel | 75,364 | $256K | 11.2% | No | Too little history (no open-market trades in 2023) |
| 2026-08-18 | Wilson Martin | General Counsel | 631 | $2K | 0.1% | No | Too little history (no open-market trades in 2023) |
| 2026-08-18 | Shah Gaurav | CEO | 2,293 | $8K | 0.2% | No | Routine (sold in Feb & May each year 2023–2025; this trade is outside those months) |
| 2026-08-13 | Shah Gaurav | CEO | 2,837 | $10K | 0.2% | No | Routine (sold in Feb & May each year 2023–2025; this trade is outside those months) |
| 2026-08-13 | Wilson Martin | General Counsel | 3,493 | $12K | 0.5% | No | Too little history (no open-market trades in 2023) |
| 2026-08-11 | Stevens Christopher James | Chief Operating Officer | 36,658 | $128K | 6.8% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Chaudhuri Sarbani | See Remarks | 4,701 | $16K | 1.8% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-21 | Shah Gaurav | CEO | 55,684 | $172K | 3.7% | No | Routine (sold in Feb & May each year 2023–2025) |
| 2026-05-19 | Shah Gaurav | CEO | 2,409 | $7K | 0.2% | No | Routine (sold in Feb & May each year 2023–2025) |
| 2026-05-19 | Wilson Martin | General Counsel | 662 | $2K | 0.1% | No | Too little history (no open-market trades in 2023) |
| 2026-05-19 | Militello John | See Remarks | 384 | $1K | 0.4% | No | Routine (sold in Feb & Apr & May & Aug & Oct each year 2023–2025) |
| 2026-05-13 | Wilson Martin | General Counsel | 3,361 | $12K | 0.5% | No | Too little history (no open-market trades in 2023) |
| 2026-05-13 | Shah Gaurav | CEO | 2,728 | $10K | 0.2% | No | Routine (sold in Feb & May each year 2023–2025) |
| 2026-05-13 | Militello John | See Remarks | 855 | $3K | 0.9% | No | Routine (sold in Feb & Apr & May & Aug & Oct each year 2023–2025) |
| 2026-05-07 | Chaudhuri Sarbani | See Remarks | 17,650 | $68K | 6.2% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.57 on a 1–5 scale), 14 analysts; mean target USD 8.58 (low 2.95, high 15).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | Goldman Sachs | Upgrade | Sell → Neutral | $3 → $4 |
| 2026-10-07 | Leerink Partners | Target lowered | Market Perform | $7 → $4 |
| 2026-10-07 | Wedbush | Reiterated | Outperform | $15 |
| 2026-10-07 | Chardan Capital | Maintained | Buy | $11 |
| 2026-09-16 | Wedbush | Reiterated | Outperform | $15 |
| 2026-09-16 | Needham | Upgrade | Hold → Buy | $9 |
| 2026-09-15 | Chardan Capital | Maintained | Buy | $11 |
| 2026-09-01 | Chardan Capital | Maintained | Buy | $11 |
| 2026-08-11 | Wedbush | Target lowered | Outperform | $16 → $15 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -40.4% | -92.5% |
| S&P 500 (SPY) | +14.8% | +77.5% |
| Per year | -40.4% | -40.5% |
| Volatility (annualized) | 68.3% | 81.0% |
| Max drawdown | -58.9% (Mar 2026→Oct 2026) | -93.9% (Nov 2021→Oct 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.52 -0.10% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.54 -1.50% · IOVA (Iovance Biotherapeutics, Inc.) USD 13.87 -1.91% · PRAX (Praxis Precision Medicines, Inc) USD 255.7 -1.24% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.96 -2.17% · ABVX (Abivax SA) USD 88.08 -2.38%

## More
Full page: https://nexqual.com/RCKT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name RCKT in their own reports (relationship from RCKT's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | REGENXBIO Inc. (RGNX) | 10-K 2026-03-05 | "Prior to the maturity date, interest and principal under the 2025 Royalty Bond shall be paid quarterly to HCR solely using proceeds received from certain specified royalties, milestone payments, licen…" |

## Company outlook (8-K filed 2026-08-10)

- "Based on its current operating plan, Rocket expects its cash, cash equivalents and investments as of June 30, 2026, to fund operations into the second quarter of 2028."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.41 | $-0.41 | -2.2% | $181,820 | 5 |
| Next quarter (ends 2026-12-31) | $-0.41 | $-0.39 | +4.7% | $624,640 | 5 |
| Current fiscal year (ends 2026-12-31) | $-0.11 | $-0.90 | -88.0% | $1.1M | 4 |
| Next fiscal year (ends 2027-12-31) | $-1.30 | $-1.22 | +7.0% | $11.2M | 5 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2027-01-15 (includes earnings 2026-11-05): ±31.8%; last 8 reports averaged ±5%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2027-01-15 | 84 | 80.3% | ±31.8% |
| 2027-04-16 | 175 | 102.8% | ±59.2% |